Data from In Vivo Disease Models on Taligen Therapeutics' Pipeline Candidates to be Presented at the XXII International Complement Workshop
CAMBRIDGE, Mass., September 25, 2008 /PRNewswire/ -- Taligen Therapeutics Inc. today announced that data from disease models on several of the company's pipeline candidates will be presented next week at the XXII International Complement Workshop in Basel, Switzerland.
The data, which will be presented in eight oral and poster presentations, are the results of research conducted by the laboratories of Michael Holers, M.D., chief scientific officer of Taligen, and the company's academic collaborators in the complement research community. Five studies testing the company's fusion protein TT30 and two new compounds, a fusion protein TT32 and a monoclonal antibody mAb171, in animal models are highlighted below. These data further support Taligen's approach that targeting the alternative complement pathway can impact complement-mediated inflammatory disease processes.
:
Hideharu Sekine*, Gary Gilkeson, Stephen Tomlinson
Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 174
Barbel Rohrer*, Qin Long, Brooks Wilson, Beth Coughlin, Yuxiang Huang, Fei Qiao, Peter Tang, Kannan Kunchithapautham, Gary Gilkeson, Stephen Tomlinson
Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 202
Joshua Thurman*, Katsuyuki Takeda, Stephen Tomlinson, Erwin Gelfand, V. Michael Holers
Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 171
Carl Atkinson*, Yongquan Gong, Yuxiang Huang, Emily Pauling, Martin Goddard, Stephen Tomlinson
Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 196
:
Liudmila Kulik*, Jonathan P. Hannan, Brigitte T. Huber, V. Michael Holers
Oct. 1, 2008, Animal models (Room: Montreal), 9:30 a.m. - 9:45 a.m., Oral 49
Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that are designed to modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process. Taligen's headquarters and late-stage research and development operations are located in Cambridge, Mass. The company also maintains a drug discovery operation in Denver under Taligen's chief scientific officer Michael Holers, M.D., which closely collaborates with an international complement biology research community. For more information, visit www.taligentherapeutics.com.
Media Contacts:
David Schull or Robert Flamm, Ph.D.
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
robert.flamm@russopartnersllc.com
CONTACT: David Schull, , or Robert Flamm,Ph.D. , , both of Russo Partners, forTaligen Therapeutics Inc., +1-212-845-4271 david.schull@russopartnersllc.com robert.flamm@russopartnersllc.com
Web site: http://www.taligentherapeutics.com/
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: September 2008
